Repeated β2-Adrenergic receptor agonist therapy attenuates the response to rescue bronchodilation in a hyperoxic newborn mouse model

Neonatology

Volumn 106, Issue 2, 2014, Pages 126-132

  Raffay, Thomas ^a   Kc, Prabha ^a   Reynolds, James ^b   Di Fiore, Juliann ^a   Macfarlane, Peter ^a   Martin, Richard J ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Airway hyperreactivity; Bronchodilation; Bronchopulmonary dysplasia; Hyperoxia; Premature lung

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR; BRONCHODILATING AGENT; FORMOTEROL; LEVALBUTEROL; METHACHOLINE; SODIUM CHLORIDE; AEROSOL; ETHANOLAMINE DERIVATIVE; BETA ACTIN;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHODILATATION; BRONCHUS HYPERREACTIVITY; BRONCHUS REACTIVITY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG REEXPOSURE; FETUS LUNG MATURATION; HYPEROXIA; LUNG COMPLIANCE; LUNG INJURY; LUNG RESISTANCE; MOUSE; NEWBORN; NONHUMAN; PREMATURITY; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; TIME; TREATMENT RESPONSE; WESTERN BLOTTING; AIRWAY RESISTANCE; ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE MODEL; DOWN REGULATION; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG TOLERANCE; FEMALE; INHALATION TEST; INHALATIONAL DRUG ADMINISTRATION; LUNG; MALE; METABOLISM; PATHOPHYSIOLOGY; AMBIENT AIR; BODY WEIGHT; COMPLIANCE RESISTANCE; DENSITY; DOSE RESPONSE; LUNG MECHANICS; POTENTIAL DIFFERENCE; PROTEIN EXPRESSION; REPEAT PROCEDURE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AEROSOLS; AIRWAY RESISTANCE; ANIMALS; ANIMALS, NEWBORN; BRONCHIAL PROVOCATION TESTS; BRONCHODILATOR AGENTS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; ETHANOLAMINES; FEMALE; HYPEROXIA; LEVALBUTEROL; LUNG; LUNG COMPLIANCE; LUNG INJURY; MALE; MICE, INBRED C57BL; RECEPTORS, ADRENERGIC, BETA; TIME FACTORS;

ANIMALIA; MUS;

EID: 84902920597     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000362684     Document Type: Article

References (30)

1. Baraldi E Carraro S Filippone M: Bronchopulmonary dysplasia: definitions and longterm respiratory outcome. Early Hum Dev 2009; 85:S1-S3.
2. Reyburn B Martin RJ Prakash YS MacFarlane PM: Mechanisms of injury to the preterm lung and airway: implications for long-term pulmonary outcome. Neonatology 2012; 101: 345-352.
3. Jaakkola JJ Ahmed P Ieromnimon A Goep fert P Laiou E Quansah R Jaakkola MS: Preterm delivery and asthma: a systematic review and meta-analysis. J Allergy Clin Immunol 2006; 118: 823-830.
4. Fawke J Lum S Kirkby J Hennessy E Marlow N Rowell V Thomas S Stocks J Lung function and respiratory symptoms at 11 years in children born extremely preterm: the EPICure study. Am J Respir Crit Care Med 2010; 182: 237-245.
5. Halvorsen T Skadberg BT Eide GE Roksund O Aksnes L Oymar K: Characteristics of asthma and airway hyper-responsiveness after premature birth. Pediatr Allergy Immunol 2005; 16: 487-494.
6. Siltanen M Savilahti E Pohjavuori M Kajosaari M: Respiratory symptoms and lung function in relation to atopy in children born preterm. Pediatr Pulmonol 2004; 37: 43-49.
7. Baraldi E Filippone M: Chronic lung disease after premature birth. N Engl J Med 2007; 357: 1946-1955.
8. Baraldi E Bonetto G Zacchello F Filippone M: Low exhaled n itric oxide in school-age children with bronchopulmonary dysplasia and airflow limitation. Am J Respir Crit Care Med 2005; 171: 68-72.
9. Carraro S Piacentini G Lusiani M Uyan ZS Filippone M Schiavon M Boner AL Baraldi E: Exhaled air temperature in children with bronchopulmonary dysplasia. Pediatr Pulmonol 2010; 45: 1240-1245.
10. Hack M Taylor HG Drotar D Schluchter M Cartar L Andreias L Wilson-Costello D Klein N: Chronic conditions functional limitations and special health care needs of school-aged children born with extremely low-birth-weight in the 1990s. JAMA 2005; 294: 318-325.
11. Yuksel B Greenough A: Variable response to bronchodilator therapy in young children born prematurely. Respir Med 1993; 87: 359-364.
12. Martin RJ Fanaroff AA Walsh MC: Fanaroff and Martin's neonatal-perinatal medicine: diseases of the fetus and infant ed 9. St. Louis Mosby/Elsevier 2011.
13. Mhanna MJ Patel JS Patel S Cohn R: The effects of racemic albuterol versus levalbuterol in very low birth weight infants. Pediatr Pulmonol 2009; 44: 778-783.
14. Mandy G Malkar M Welty SE Brown R Shepherd E Gardner W Moise A Gest A: Tracheostomy placement in infants with bronchopulmonary dysplasia: safety and outcomes. Pediatr Pulmonol 2013; 48: 245-249.
15. Gomez-Del Rio M Gerhardt T Hehre D Feller R Bancalari E: Effect of a beta-agonist nebulization on lung function in neonates with increased pulmonary resistance. Pediatr Pulmonol 1986; 2: 287-291.
16. Rieger-Fackeldey E Reinhardt D Schulze A: Effects of inhaled formoterol compared with salbutamol in ventilated preterm infants. Pulm Pharmacol Ther 2004; 17: 293-300.
17. Denjean A Paris-Llado J Zupan V Debillon T Kieffer F Magny JF Desfreres L Llanas B Guimaraes H Moriette G et al: Inhaled salbutamol and beclomethasone for preventing broncho-pulmonary dysplasia: a randomised double-blind study. Eur J Pediatr 1998; 157: 926-931.
18. Motoyama EK Fort MD Klesh KW Mutich RL Guthrie RD: Early onset of airway reactivity in premature infants with bronchopulmonary dysplasia. Am Rev Respir Dis 1987; 136: 50-57.
19. Salp eter SR Ormiston TM Salpeter EE: Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med 2004; 140: 802-813.
20. Amy RW Bowes D Burri PH Haines J Thurlbeck WM: Postnatal growth of the mouse lung. J Anat 1977; 124: 131-151.
21. Warner BB Stuart LA Papes RA Wispe JR: Functional and pathological effects of prolonged hyperoxia in neonatal mice. Am J Physiol 1998; 275:L110-L117.
22. Takeda K Okamoto M de Langhe S Dill E Armstrong M Reisdorf N Irwin D Koster M Wilder J Stenmark KR et al: Peroxisome proliferator-activated receptor-g agonist treatment increases septation and angiogenesis and decreases airway hyperresponsiveness in a model of experimental neonatal chronic lung disease. Anat Rec 2009; 292: 10 45-1061.
23. Shalaby KH Gold LG Schuessler TF Martin JG Robichaud A: Combined forced oscillation and forced expiration measurements in mice for the assessment of airway hyperresponsiveness. Respir Res 2010; 11: 82.
24. Raffay TM Locy ML Hill CL Jindal NS Rogers LK Welty SE Tipple TE Neonatal hyperoxic exposure persistently alters lung secretoglobins and annexin A1 Biomed Res In t 2013 2013 408485.
25. Choi CW Kim BI Mason SN Potts-Kant EN Brahmajothi MV Auten RL: Intra-amniotic LPS amplifies hyperoxia-induced airway hyperreactivity in neonatal rats. Pedia tr Res 2013; 74: 11-18.
26. O'Reilly M Harding R Sozo F: Altered small airways in aged mice following neonatal exposure to hyperoxic gas. Neonatology 2014; 105: 39-45.
27. Lundblad LK Rinaldi LM Poynter ME Riesenfeld EP Wu M Aimi S Barone LM Bates JH Irvin CG: Detrimental effects of albuterol on airway responsiveness requires airway inflammation and is independe nt of beta-receptor affinity in murine models of asthma. Respir Res 2011; 12: 27.
28. Lin R Degan S Theriot BS Fischer BM Strachan RT Liang J Pierce RA Sunday ME Noble PW Kraft M et al: Chronic treatment in vivo with beta-adrenoceptor agonists induces dysfunction of airway beta(2)-adrenoceptors and exacerbates lung inflammation in mice. Br J Pharmacol 2012; 165: 2365-2377.
29. Newnham DM McDevitt DG Lipworth BJ: Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med 1994; 97: 29-37.
30. Giubergia V Gravina LP Castanos C Chertkoff L Grenoville M: Influence of beta2-adrenoceptor polymorphisms on the response to chronic use of albuterol in asthmatic children. Pediatr Pulmonol 2008; 43: 421-425.